GoodRx Holdings (GDRX) Research & Development (2019 - 2026)

GoodRx Holdings has disclosed Research & Development across 8 years of filings, most recently posting $30.2 million for Q1 2026.

• Research & Development for Q1 2026 came in at $30.2 million, down 3.1% year-over-year; the trailing twelve-month figure through Mar 2026 was $120.1 million (down 3.08% YoY), and the FY2025 annual result was $121.0 million, down 2.2% from the prior year.
• Research & Development came in at $30.2 million for Q1 2026 at GoodRx Holdings, up from $28.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $39.6 million in Q3 2023 to a low of $28.9 million in Q4 2025.
• The 5-year median for Research & Development is $31.3 million (2023), against an average of $32.6 million.
• Across the five-year window, Research & Development soared 33.95% in 2022 and retreated 23.91% in 2024, its largest moves.
• GoodRx Holdings' Research & Development stood at $36.8 million in 2022, then dropped by 12.89% to $32.0 million in 2023, then fell by 0.91% to $31.7 million in 2024, then dropped by 8.82% to $28.9 million in 2025, then increased by 4.28% to $30.2 million in 2026.
• The last three Research & Development figures came in at $30.2 million (Q1 2026), $28.9 million (Q4 2025), and $31.0 million (Q3 2025), per Business Quant data.